Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix, Inc. (Nasdaq: BDSX) is a diagnostic solutions company with a strong focus on lung disease and oncology, and its news flow reflects that specialization. Company updates frequently cover performance of its lung diagnostics business, including revenue trends, test volumes, and reimbursement developments for its Biodesix Diagnostic Tests marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance.
Investors and clinicians following BDSX news can expect regular financial and operating results releases, where Biodesix reports revenue from Lung Diagnostics and Development Services, discusses gross margins, and comments on measures such as Adjusted EBITDA. These announcements often describe factors influencing growth, such as increased test adoption, payer coverage, and expansion into clinical settings like pulmonology and primary care.
Biodesix also issues news about its Development Services activities and partnerships with biopharmaceutical and life sciences companies. Recent items include an expanded agreement to develop and clinically validate Droplet Digital PCR high complexity assays on Bio-Rad platforms, as well as availability of an ultra-sensitive ESR1 assay for biopharma customers and clinical use in advanced breast cancer.
Another recurring theme in BDSX news is scientific and medical conference participation. The company highlights poster presentations, workshops, and corporate events at meetings focused on lung cancer, breast cancer, pharmacoeconomics, and molecular pathology. These stories showcase new clinical utility data for Nodify Lung tests, health economic analyses of pulmonary nodule management, and research on molecular diagnostic technologies such as NGS, ddPCR, and mass spectrometry.
In addition, Biodesix reports on corporate and capital markets developments, including reverse stock split actions and Nasdaq listing compliance updates, as well as investor conference participation. For users tracking BDSX, this news page provides a centralized view of operational performance, scientific progress, collaborations, and key corporate milestones over time.
Biodesix, Inc. (NASDAQ: BDSX) has been recognized as the leading Proteomics Solutions Company in the U.S. by Life Sciences Review Magazine in its December 2022 issue. With over 15 years in clinical proteomics, Biodesix specializes in identifying patients' immune responses to cancer using blood-based tests. The company has performed over 125,000 proteomic tests and currently offers three clinical tests, enabling faster and more accurate diagnosis and treatment strategies for lung cancer. This recognition underscores Biodesix's commitment to advancing diagnostic solutions in lung disease.
Biodesix, Inc. (NASDAQ: BDSX) has announced the pricing of a public offering of 30,500,000 shares at $1.15 each, aiming to raise approximately $35.1 million. The offering, expected to close on November 21, 2022, includes an option for underwriters to purchase an additional 4,575,000 shares. Biodesix will utilize the funds to enhance its data-driven diagnostic solutions for lung disease, developed through multi-omics and AI technologies.
Biodesix, Inc. (NASDAQ: BDSX) has initiated an underwritten public offering of $30 million in common stock. The company may offer an additional $4.5 million of shares if underwriters exercise their option. The proceeds will fund commercial expansion, support R&D, and cover general corporate expenses. The offering is subject to market conditions and other factors. William Blair is the sole bookrunning manager. The shares will be sold under a shelf registration statement filed with the SEC in November 2021.
Biodesix (BDSX) has secured a $50 million term loan facility from Perceptive Advisors. The financing includes $30 million as initial funding and a potential $20 million based on future milestones. This move aims to strengthen the company's balance sheet and enhance liquidity by providing a five-year interest-only repayment period. Funds will support debt repayment, working capital, and commercialization of five Medicare-covered lung diagnostic tests, positioning Biodesix for continued growth in the lung disease diagnostic market.
Biodesix announces new interim data from the INSIGHT study, presented by Dr. Wallace Akerley at the SITC 37th Annual Meeting on November 11, 2022. The study confirms the VeriStrat test's ability to predict outcomes in patients with Non-small Cell Lung Cancer (NSCLC) treated with immunotherapy. Analysis of 3,040 patients shows that HIC-C classification results in better median overall survival when combined with chemotherapy. The data underscores the importance of biomarker-driven strategies for optimal treatment.
Biodesix reported a 102% increase in core lung diagnostic revenue to $9.2 million for Q3 2022 compared to Q3 2021. Total revenue reached $11.1 million, up 70% year-over-year, driven by strong adoption of Nodify tests. Medicare now covers all five core lung diagnostic tests, enhancing growth prospects. Despite a net loss of $13.7 million, a decrease in operating loss indicates improved financial health. Cash reserves stand at $15.2 million. The company expects to meet its revenue guidance of $37.5-$39.5 million for 2022, emphasizing growth in lung diagnostics.
Biodesix, a diagnostic solutions company focused on lung disease, will release its Q3 financial results on November 3, 2022. The results will be made public before the market opens, followed by a conference call at 8:00 a.m. ET for a business update and Q&A session. Biodesix offers five Medicare-covered tests using advanced AI for lung disease diagnostics, which aids in treatment decisions and risk assessments for malignancies.
Biodesix announced a Federal Supply Schedule contract with the Veterans Health Administration to provide its lung diagnostic portfolio. This includes tests such as Nodify XL2® and GeneStrat®. The U.S. Department of Veterans Affairs serves over 9 million veterans, and the partnership aims to improve lung cancer care for this population, which has a higher risk of the disease. The company emphasizes its commitment to advancing diagnostic solutions in lung disease, leveraging AI capabilities to enhance patient outcomes.
Biodesix (Nasdaq: BDSX) announced new findings from the Nodify XL2® proteomic test at the CHEST 2022 Annual Meeting, showcasing its effectiveness in evaluating the malignancy risk of pulmonary nodules. Data from the ORACLE study indicates the test performs equally well for nodules identified through lung cancer screenings and incidental findings. With the expansion of eligibility for lung cancer screening in the U.S., the test could help reduce unnecessary biopsies for benign nodules. The presentations highlight the role of blood-based testing in more accurate risk stratification.
Biodesix (BDSX) reported strong preliminary results for Q3 2022, with estimated total revenues between $10.6 million and $11.2 million, marking a 62% to 71% increase from Q3 2021. Core lung diagnostic testing revenues surged 96% to 103%, reaching $8.9 million to $9.2 million. Meanwhile, COVID diagnostic revenues saw significant growth, but are expected to decline due to contract expirations. The company maintains a strong cash position of $15.2 million as of September 30, 2022.